Skip to content

Single-cell omics and Al-fueled discovery to help endometriosis patients

Single-cell omics and Al-fueled discovery to help endometriosis patients

Single-cell omics and Al-fueled discovery to help endometriosis patients

Single-cell omics and Al-fueled discovery to help endometriosis patients

Scailyte’s powerful single-cell AI platform, ScaiVision, has played a pivotal role in a groundbreaking move in the field of endometriosis. Hera Biotech is set to acquire and bring to the patients Scailyte’s endometriosis diagnostic assets, marking a significant milestone in non-surgical diagnosis of endometriosis.

Leveraging the biggest single-cell RNAseq dataset in endometriosis and our best-in-class biomarker discovery platform, ScaiVision, we have identified highly accurate biomarkers for the diagnosis of endometriosis. Unlike conventional methods for analysis and interpretation of single-cell data that start with cell clustering and cell type annotation, ScaiVision is using an unbiased representation learning method that allows ultra-sensitive discovery of novel biology. 

Following the discovery of the disease-associated gene signatures and cell phenotypes from single-cell data, we went through several translational steps and prototyped a conventional and scalable qPCR assay, which Hera Biotech will now validate further and deploy in clinical laboratories in the USA. 

Reach out if you want to learn more about ScaiVision and how we can partner to make groundbreaking discoveries leveraging multi-omics data and our proprietary AI platform!

In a stride towards non-surgical endometriosis diagnosis, Hera Biotech has announced its impending acquisition of endometriosis diagnostic assets from Scailyte, a company active in single-cell and AI-driven biomarker discovery. This acquisition marks a notable consolidation in the tissue-based diagnostic landscape for endometriosis, a prevalent condition contributing to a significant portion of female infertility and characterized by severe pain due to the abnormal growth of uterine-like tissue outside the uterus.

Standard diagnosis methods involve invasive laparoscopic surgery, leading to delayed diagnosis. However, the collaborative research between Hera Biotech and Scailyte, along with their academic partners, has led to the development of complementary biomarkers and assays, presenting a more direct, accurate, and non-invasive diagnostic approach. This consolidation is expected to speed up the creation of clinical tools for diagnosing and stratifying endometriosis patients and facilitate the development of targeted therapies.

Scailyte CEO, Dr. Peter Nestorov, commented: “We are excited to work with Hera to integrate Scailyte’s endometriosis assets into the Hera pipeline. Through our collaboration with Prof. Michael Mueller from the University of Bern, we have generated the largest single-cell RNAseq datasets from peripheral blood and endometrial tissue. The insights we gained clearly indicate that the tissue-based approach is the only way to capture the complexity and heterogeneity of endometriosis, and therefore tissue-based molecular assays will be the only viable alternative to laparoscopy for a definitive diagnosis and patient stratification.”

The initial product in the combined portfolio utilizes Scailyte’s deep sequencing discovery platform, promising a highly specific and robust diagnostic assay for endometriosis. Hera Biotech aims to launch this product in the US fertility market by late 2024, followed by another product for the definitive diagnosis and staging of endometriosis in the OB/GYN market.

We are delighted that this partnership also affords Hera the opportunity to add Dr. Cinzia Donato to our executive team and Professor Michael Mueller to our scientific advisory board. Dr. Donato and Professor Mueller were the driving forces behind Scailyte’s endometriosis diagnostic program and bring a breadth of scientific and commercial skills to complement Hera’s in-house diagnostic programs. We are excited to announce this partnership in conjunction with our $15M Series A raise, which we are kicking off at the JP Morgan Healthcare conference next week,” said Somer Baburek, CEO Hera Biotech.

The transaction is expected to be finalized by the end of January 2024, post the completion of due diligence.

About Scailyte

Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets. 

Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.

For more information, visit www.scailyte.com and connect on social media @LinkedIn and @Twitter.

ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG.

Recent News

Meet Scailyte at Immuno-Oncology 360° in New York, USA

Our very own Diana Stoycheva and Peter Nestorov will be representing Scailyte at the conference at b...

Read more

Recent News

Inside Scailyte – Episode 5: Meet Daniel Schoener

Join us as we introduce you to Daniel Schoener, Executive Business Advisor at Scailyte AG. Daniel's ...

Read more

Recent News

ScaiDigest Volume 7: Unveiling Insights into Autoimmune Diseases

We're thrilled to share the latest installment of our ScaiDigest series, authored by our very own Di...

Read more

Recent News

Inside Scailyte – Episode 4: Meet Peter Evans

In this special episode, we introduce you to Peter Evans, our Principal IT Engineer at Scailyte AG. ...

Read more

Recent News

Inside Scailyte – Episode 3: Meet Peter Nestorov

Join us as Peter Nestorov, the Founder and CEO of Scailyte shares the pivotal role of Scailyte in th...

Read more

Recent News

Festival of Genomics 2024

Scailyte will be a part of the upcoming Festival of Genomics, on January 24th and 25th, 2024, in Lon...

Read more

Recent News

Inside Scailyte - Episode 2: Filipa Teixeira

We're back with another exciting episode of "Inside Scailyte," where we delve into the incredible jo...

Read more

Recent News

Single-cell omics and Al-fueled discovery to help endometriosis patients

Scailyte's powerful single-cell AI platform, ScaiVision, has played a pivotal role in a groundbreaki...

Read more

Recent News

01 /04

Meet Scailyte at Immuno-Oncology 360° in New York, USA

Our very own Diana Stoycheva and Peter Nestorov will be representing Scailyte at the conference at b...

Read more

Inside Scailyte – Episode 5: Meet Daniel Schoener

Join us as we introduce you to Daniel Schoener, Executive Business Advisor at Scailyte AG. Daniel's ...

Read more

Recent News

02 /04

ScaiDigest Volume 7: Unveiling Insights into Autoimmune Diseases

We're thrilled to share the latest installment of our ScaiDigest series, authored by our very own Di...

Read more

Inside Scailyte – Episode 4: Meet Peter Evans

In this special episode, we introduce you to Peter Evans, our Principal IT Engineer at Scailyte AG. ...

Read more

Recent News

03 /04

Inside Scailyte – Episode 3: Meet Peter Nestorov

Join us as Peter Nestorov, the Founder and CEO of Scailyte shares the pivotal role of Scailyte in th...

Read more

Festival of Genomics 2024

Scailyte will be a part of the upcoming Festival of Genomics, on January 24th and 25th, 2024, in Lon...

Read more

Recent News

04 /04

Inside Scailyte - Episode 2: Filipa Teixeira

We're back with another exciting episode of "Inside Scailyte," where we delve into the incredible jo...

Read more

Single-cell omics and Al-fueled discovery to help endometriosis patients

Scailyte's powerful single-cell AI platform, ScaiVision, has played a pivotal role in a groundbreaki...

Read more

Recent News